A Lifestyle and Combination Medication Therapy Diabetes Prevention Study
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
It is now well established that the 21st century will be characterized by a global epidemic
of Type 2 diabetes. The principal aim of the CANOE study is to determine whether individuals
with the pre-diabetes condition impaired glucose tolerance can be prevented from progressing
to diabetes with a healthy living lifestyle intervention and an insulin sensitizing
medication. Individuals who have impaired glucose tolerance (IGT) determined during an oral
glucose tolerance test will be eligible to participate in this study. All participants will
receive a lifestyle dietary and exercise intervention program. Half of the participants will
be randomly assigned to an insulin sensitizing medication (rosiglitazone/metformin) which is
commonly used to treat Type 2 diabetes. The primary outcome for this study is the development
of diabetes. The study is expected to last a total of five years.
Phase:
Phase 3
Details
Lead Sponsor:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital